(VIANEWS) - Ultrapar Participacoes S.A. (UGP), Booking Holdings (BKNG), Genmab (GMAB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Ultrapar Participacoes S.A. (UGP)
59.8% sales growth and 9.53% return on equity
Ultrapar ParticipaASSAues S.A. is involved in gas distribution and fuel distribution. It also sells chemicals, storage and drugsstores business primarily in Brazil and Mexico. The company's Gas Distribution segment sells liquefied petroleum to commercial and residential customers, primarily in Brazil's South, Southeast and Northeast regions. Fuel Distribution, the company, distributes gasoline, ethanol and diesel as well as fuel oil and other lubricants. It also operates convenience stores and provides lubricant-changing services and auto specialized services. The Chemicals segment manufactures ethylene oxide, its derivatives and fatty alcohols. These are the raw materials for home care and personal care as well as paints and varnishes. Its Storage segment manages liquid bulk terminals, primarily in Brazil's Northeast and Southeast regions. The company's Drugstores segment sells pharmaceutical, beauty, and hygiene products via its own chain of drugstores located in Brazil's Northeast, Northeast, and Southeast. The company had 7,107 Ipiranga stations, 1,804 AmPm convenience shops; 1,172 Jet Oil franchises, 405 Extrafarma pharmacy stores and 3 distribution centres as of December 31, 2020. It also operated 6 Ultracargo terminals that have a storage volume of 838 million cubic meters. Abastece AA is a digital payment app. Km de Vantagens is a loyalty program. It was established in Brazil in 1937. The headquarters are located in SAPSo Paulo.
Earnings Per Share
As for profitability, Ultrapar Participacoes S.A. has a trailing twelve months EPS of $0.17.
PE Ratio
Ultrapar Participacoes S.A. has a trailing twelve months price to earnings ratio of 12.88. Meaning, the purchaser of the share is investing $12.88 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.53%.2. Booking Holdings (BKNG)
47.4% sales growth and 11.38% return on equity
Booking Holdings Inc. offers online reservations for travel and restaurants worldwide. Booking.com offers accommodation bookings online; Rentalcars.com provides rental car services online; Priceline which allows customers to make travel reservations online for hotel, flight and rental cars. Agoda, which offers online accommodations reservation, flight, ground transport, and activity reservation services, is also available. KAYAK is an online price comparison site that lets consumers search for and compare prices on travel itineraries. This includes information about rental cars, airline tickets, hotel reservations, and accommodation. OpenTable allows customers to book online restaurants. It also offers insurance and management services for consumers and travel service providers. The original name of the company was The Priceline Group Inc., but it changed its name in February 2018 to Booking Holdings Inc. It was established in 1997. The headquarters are located in Norwalk in Connecticut.
Earnings Per Share
As for profitability, Booking Holdings has a trailing twelve months EPS of $1.44.
PE Ratio
Booking Holdings has a trailing twelve months price to earnings ratio of 1162.27. Meaning, the purchaser of the share is investing $1162.27 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.38%.Yearly Top and Bottom Value
Booking Holdings's stock is valued at $1,673.67 at 11:22 EST, way below its 52-week high of $2,715.66 and higher than its 52-week low of $1,616.85.
3. Genmab (GMAB)
24.4% sales growth and 11.1% return on equity
Genmab A/S is a Danish company that develops and markets antibody therapies for cancer treatment. DARZALEX is a monoclonal human antibody that can be used to treat multiple myeloma. Teprotumumumab is for treatment of thyroid disease. Ofatumurnab (a human monoclonal anti-body for chronic lymphocyticleukemia (CLL), multiple sclerosis) and Amivantamab (for advanced, metastatic, or esophageal, cancers and NSCLC) are also available. Daratumumab is used to treat MM and non-MM blood tumors and AL Amyloidosis. It also produces products. Phase 2 includes Teclistamab to treat vaso-occlusive crisis; Camidanlumab tesirine for treatment of hodgkin lymphoma; JNJ-64407564 for treatment of MM; PRV-015 to treat celiac disorder; Mim8 to treat haemophilia; and Lu AF82422 to treat multiple system atrophy. It also has 20 preclinical trials. Seagen Inc. has granted the company a collaboration and commercial license to develop tisotumab. The company also has a partnership agreement with CureVac AG to research and develop differentiated mRNA-based antibodies products. AbbVie is responsible for developing epcoritamab. There are collaborations with BioNTech, Janssen, Novo Nordisk A/S, Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999. Its headquarters are in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.66.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 55.3. Meaning, the purchaser of the share is investing $55.3 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.1%.Revenue Growth
Year-on-year quarterly revenue growth grew by 34%, now sitting on 9.02B for the twelve trailing months.
Growth Estimates Quarters
The company's growth estimates for the ongoing quarter and the next is 1028.6% and 570.4%, respectively.Moving Average
Genmab's value is higher than its 50-day moving average of $35.37 and above its 200-day moving average of $34.10.Yearly Top and Bottom Value
Genmab's stock is valued at $36.56 at 11:22 EST, way under its 52-week high of $47.28 and way above its 52-week low of $26.19.
4. Telefonica Brasil, S.A. ADS (VIV)
12.6% sales growth and 7.95% return on equity
TelefA'nica Brasil S.A. and its subsidiaries provide mobile and fixed telecom services for residential and business customers in Brazil. Fixed line services include long distance calls, both domestic and international, as well as local and long-distance calling. The mobile portfolio offers voice and broadband access via 3G, 4G and 4.5G. Data services include broadband and mobile data. It also offers pay TV services via satellite, IPTV and cable. The company also offers multi-media communication services that include audio, data and voice as well as images, text, sounds and other sounds. It also sells products such as smartphones and broadband USB modems. It also provides IT support and telecommunications solutions to various industries such as manufacturing, finance, retail, service, government, and services. The company markets its products through dealers, own shops, retailers, distribution channels, door to door sales and outbound telephone sales. The original name of the company was TelecomunicaASSAues de SAPSo Paulo S.A.- TELESP. In October 2011, TelefA'nica Brasil S.A. took over. It was founded in 1998. The headquarters are located in SAPSo Paulo in Brazil.
Earnings Per Share
As for profitability, Telefonica Brasil, S.A. ADS has a trailing twelve months EPS of $0.61.
PE Ratio
Telefonica Brasil, S.A. ADS has a trailing twelve months price to earnings ratio of 12.33. Meaning, the purchaser of the share is investing $12.33 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.95%.Revenue Growth
Year-on-year quarterly revenue growth grew by 11.1%, now sitting on 45.72B for the twelve trailing months.
Sales Growth
Telefonica Brasil, S.A. ADS's sales growth is 7.4% for the current quarter and 12.6% for the next.
5. Glacier Bancorp (GBCI)
12.1% sales growth and 10.31% return on equity
Glacier Bancorp, Inc. is the holding bank company of Glacier Bank. It provides banking services for individuals, small- to medium-sized business, community groups, government entities, and other public bodies in the United States. The company offers both interest-bearing and non-interest-bearing deposit accounts. These include savings accounts and money market deposits accounts. Fixed rate certificates of deposit with fixed rates, negotiated-rate certificates and individual retirement accounts. It also offers residential construction loans and loans for permanent construction. It also offers loans for commercial real property, including loans to buy, build, and finance commercial properties. The company also offers mortgage servicing and origination services. There are 224 locations including 188 branches, 36 loan/administration offices and 188 branch locations in all 8 states, which includes Montana, Idaho and Utah. Kalispell is the headquarters of this company, which was established in 1955.
Earnings Per Share
As for profitability, Glacier Bancorp has a trailing twelve months EPS of $3.18.
PE Ratio
Glacier Bancorp has a trailing twelve months price to earnings ratio of 16.21. Meaning, the purchaser of the share is investing $16.21 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.31%.Yearly Top and Bottom Value
Glacier Bancorp's stock is valued at $51.60 at 11:22 EST, way under its 52-week high of $60.69 and way above its 52-week low of $44.43.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 10, 2022, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 2.64%.
6. Ashland (ASH)
5.7% sales growth and 4.79% return on equity
Ashland Global Holdings Inc. supplies specialty and additive ingredients around the world. The company operates in three segments: Life Sciences, Personal Care & Household, Specialty Additives and Intermediates and Solvents. Life Sciences offers pharmaceutical solutions including disintegrants and thickeners for tablet coatings and tablets, thickeners and solubilizers for tablet bindings and thickeners. Nutrition solutions include thickeners and stabilizers as well as nutraceutical products that can be used to manage weight, joints, digestive health, stomach and intestinal function, sport nutrition and overall wellness. Personal Care & Household offers a variety of biodegradable and performance ingredients. These include solutions for dentures cleaning and toothpastes; household supplies that are derived from nature, such as biodegradable surfaces wetting agents and specialty polymers. Specialty Additives offers advanced ceramics that are used in catalytic converters and environmental filters. It also includes rheology modifiers and foam control agents as well as surfactants, wetting agents and wetting agents. Intermediates and Solvents produces 1,4 Butanediol and its derivatives including n-methylpyrrolidone. Ashland Global Holdings Inc. sells its products in many markets including industrial and consumer markets such as architecture, building, energy, food, beverage, nutraceuticals and personal care. In September 2016, Ashland Inc. was the company's name. Ashland Global Holdings Inc. is located in Wilmington, Delaware.
Earnings Per Share
As for profitability, Ashland has a trailing twelve months EPS of $2.67.
PE Ratio
Ashland has a trailing twelve months price to earnings ratio of 35.67. Meaning, the purchaser of the share is investing $35.67 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.79%.